Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

MicroPort Co-Leads $20 Million Investment in Israel's Rapid Medical

publication date: Apr 25, 2019

MicroPort, a Shanghai medical device company, co-led a $20 million Series C financing in Rapid Medical, an Israeli company developing a stentreiver treatment for stroke. As part of the agreement, MicroPort will partner with Rapid Medical to develop the treatment in China. Rapid Medical said it would use the funding to complete a US IDE study and support the commercial growth of the stroke treatment globally. The C round was co-led by JAM Capital Partners with participation from Agate JT, RocSon Medtech Fund and existing investors. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China